SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Zobair M. Younossi, Yushan Jiang, Nathaniel J. Smith, Maria Stepanova, Rachel Beckerman, Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States, Hepatology, 2015, 61, 5
  2. 2
    Ann-Sofi Duberg, Sarah Blach, Karolin Falconer, Martin Kåberg, Homie Razavi, Soo Aleman, The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies, Scandinavian Journal of Gastroenterology, 2015, 50, 2, 233

    CrossRef

  3. 3
    Susanne Sarkar, Martin Schaefer, Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis, Psychosomatics, 2014, 55, 3, 221

    CrossRef

  4. 4
    George V. Papatheodoridis, Emmanuel Tsochatzis, Svenja Hardtke, Heiner Wedemeyer, Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review, Liver International, 2014, 34, 10
  5. 5
    Vivien A. Sheehan, Alva Weir, Bradford Waters, Hepatitis C and neutropenia, Current Opinion in Hematology, 2014, 21, 1, 58

    CrossRef

  6. 6
    Keyur Patel, Katja S. Remlinger, Terence G. Walker, Peter Leitner, Joseph E. Lucas, Stephen D. Gardner, John G. McHutchison, Will Irving, Indra Neil Guha, Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, 2014, 12, 12, 2113

    CrossRef

  7. 7
    Timothy A. Stammers, René Coulombe, Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, Sylvie Goulet, Araz Jakalian, Steven LaPlante, Jean Rancourt, Bounkham Thavonekham, Dominik Wernic, George Kukolj, Pierre L. Beaulieu, Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 24, 6879

    CrossRef

  8. 8
    A. Aghemo, P. Lampertico, Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 38, 5
  9. 9
    A. H. Talal, J. LaFleur, R. S. Hoop, P. Pandya, P. Martin, I. M. Jacobson, J. Han, E. J. Korner, Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply, Alimentary Pharmacology & Therapeutics, 2013, 38, 5
  10. You have free access to this content10
    S. C. Gordon, F. M. Hamzeh, P. J. Pockros, R. S. Hoop, A. R. Buikema, E. J. Korner, N. A. Terrault, Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease, Alimentary Pharmacology & Therapeutics, 2013, 38, 7